Moreover, in vivo experiments showed that nintedanib suppressed the α-SMA-positive staining area in tumours, and that combination therapy with gemcitabine inhibited tumour growth to an even greater extent compared with single-agent treatment. This evidence concerns the gene ACTA1 and neoplasm.